>>Micro, not sure why you think synergy is a big deal for Onxx when the key is to have a second drug that sells well.<<
Onyx is unprofitable with one drug; it may be unprofitable - or marginally unprofitable with two. So of course sales & marketing synergies are important. If you were a drug company, would you want to spend hundreds of millions of dollars per year on a sales force with each rep only selling a single drug??
>>I expect other deals in Asia and Europe.<<
Onyx plans to market Carfilzomib in Europe and outlicense it in Asia.
Market Data 
Markets 
AI
